This conclusion is based on the analysis of the acquisition of HLA loss of heterozygosity; HLA loss of heterozygosity occurs in about 40% of NSCLCs and is associated with a high tumor burden, APOBEC-mediated mutagenesis, upregulation of cytolytic activity, and PD-L1 positivity [91]. The gene discussed is CD274; the disease is neoplasm.